These are the two names that come up constantly once you start researching GLP-1 weight loss medications, and for good reason. Both are FDA-approved, both drive significant weight loss, and both come from major pharmaceutical companies with a lot of research behind them. The honest answer to which one is right for you depends on a few specific factors, not a simple better-or-worse ranking.

Zepbound vs. Wegovy: What's the Difference?

Wegovy contains semaglutide, made by Novo Nordisk. It's a GLP-1 receptor agonist, meaning it works on one hormone pathway involved in appetite and blood sugar regulation. Wegovy is available as a weekly injection, and as of late 2025, an oral pill version as well.

Zepbound contains tirzepatide, made by Eli Lilly. It's a dual GLP-1 and GIP receptor agonist, working on two hormone pathways instead of one. Zepbound is currently available only as a weekly injection.

Which One Works Better for Weight Loss?

This is where the data actually gives a clear answer. In SURMOUNT-5, a head-to-head clinical trial that put tirzepatide and semaglutide against each other directly in the same study, tirzepatide produced significantly greater weight loss. Participants on tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for those on semaglutide. Tirzepatide also outperformed semaglutide on several secondary measures, including blood pressure, cholesterol markers, and the percentage of people who lost at least a quarter of their starting body weight.

According to the American College of Cardiology's coverage of the trial, these results held up across multiple measures, not just the scale. That said, averages describe a study population, not a guarantee for any one person. Individual response to either medication varies, sometimes significantly.

How Do the Side Effects Compare?

Both medications share a similar side effect profile because both slow gastric emptying. Nausea, constipation, and other GI symptoms show up with both drugs, usually most noticeably around dose increases. Adding the GIP mechanism in tirzepatide doesn't appear to make tolerability meaningfully worse in most people, and discontinuation rates due to side effects were similar between the two arms of the SURMOUNT-5 trial.

Zepbound vs. Wegovy at a Glance

How Do Dosing and Titration Compare?

Both medications start at a low dose and increase gradually, a process called titration, to help your body adjust and reduce side effects. Wegovy typically titrates over about 16 to 20 weeks before reaching a maintenance dose. Zepbound follows a similar step-up schedule, usually over a comparable timeframe, with your provider adjusting the pace based on how you're tolerating each increase.

Neither medication is meant to be rushed to a higher dose. Skipping steps in the titration schedule is one of the more common reasons people experience worse side effects than necessary, regardless of which medication they're on.

Which One Is More Likely to Be Covered by Insurance?

Insurance coverage for both medications has been inconsistent and depends heavily on your specific plan, your employer, and whether your diagnosis supports medical necessity. Neither Zepbound nor Wegovy has a clear, universal advantage here, coverage tends to come down to your plan's formulary and whether it treats weight management medication as a covered benefit at all, rather than which specific drug you're prescribed. Some plans that exclude weight-loss coverage entirely will still cover the same medication when prescribed for an FDA-approved indication like type 2 diabetes or obstructive sleep apnea, which is worth asking your provider about if you have a qualifying condition.

If your plan denies coverage, both Novo Nordisk and Eli Lilly have appeals resources and prior authorization support available directly through their websites, and your prescribing provider's office can often help submit the paperwork.

What Does Long-Term Maintenance Look Like for Each?

Both medications are intended for long-term use once you reach a maintenance dose, not a short course. Stopping either one typically leads to at least partial weight regain over time, which is consistent with how the underlying appetite and metabolic signaling works. Maintenance dosing is usually the highest tolerated dose from your titration schedule, continued indefinitely under provider supervision, with periodic check-ins to reassess whether the dose, or the medication itself, still fits your goals and health status.

Some patients and providers explore a lower maintenance dose once a weight goal is reached, rather than stopping altogether, as a way to support the results without necessarily staying at the highest dose indefinitely. This is very individual and should be a collaborative decision with your provider rather than something to adjust on your own.

How Does Cost Factor In?

Here's where the decision gets more personal. Wegovy currently has a lower starting self-pay price through Novo Nordisk's own pharmacy program, while Zepbound's self-pay pricing through Lilly's direct pharmacy tends to run somewhat higher. If you're paying out of pocket, it's worth reading the full breakdown of GLP-1 pricing without insurance before deciding, since the stronger average results with tirzepatide don't necessarily make it the better value for everyone.

Which Should You Choose?

If maximizing the average amount of weight loss is your top priority and you're comfortable with a weekly injection, Zepbound has the stronger head-to-head data behind it. If cost, the option of a daily pill, or simply how your body responds matters more, Wegovy may be the better fit. Some people also respond better to one mechanism than the other in ways clinical trial averages can't predict, which is part of why this decision should be made with a provider rather than by the numbers alone.

It's also worth understanding how either medication interacts with your body composition over time. If you're concerned about how GLP-1 medications affect muscle mass, that's a conversation worth having regardless of which medication you choose.

Getting Started

A provider who can review your health history, goals, and prior experience with either medication is the best way to actually answer this question for your situation. Shed's weight loss programs include that evaluation along with health coaching to support whichever medication ends up being the right fit.

FAQs About Zepbound vs. Wegovy

Is Zepbound better than Wegovy?

In head-to-head trial data, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy). Whether it's the better choice for you also depends on cost, side effect tolerance, and personal response, which a provider can help evaluate.

Does Zepbound or Wegovy have fewer side effects?

Both share a similar side effect profile, primarily nausea and constipation from slowed digestion. Clinical trial data shows similar rates of people stopping treatment due to side effects for both medications.

Can I switch between Zepbound and Wegovy?

Switching is possible but should only be done with provider guidance, since dosing and titration schedules differ between the two medications.

How much do Zepbound and Wegovy cost without insurance?

Through manufacturer self-pay pharmacy programs, Wegovy typically runs $199 to $349 a month and Zepbound runs $349 to $499 a month, depending on dose.

Is Zepbound or Wegovy more likely to be covered by insurance?

Neither has a clear universal advantage. Coverage depends on your specific plan and whether it treats weight management medication as a covered benefit, more than which drug you're prescribed.

Do you have to stay on Zepbound or Wegovy forever?

Both are intended for long-term use once you reach a maintenance dose. Stopping either one typically leads to at least partial weight regain, so most providers frame these as ongoing treatments rather than a short course.

Disclaimer:

This content is provided for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. You should consult a licensed healthcare provider for evaluation and guidance specific to your situation before starting or changing any treatment, supplement, or medication.

Zepbound® and Wegovy® are registered trademarks of their respective manufacturers. Shed is an administrative platform and is not affiliated with, endorsed by, or associated with these manufacturers.

Compounded medications are not FDA-approved for safety, effectiveness, or quality and are only appropriate for patients with a documented clinical need that an FDA-approved product cannot meet.

Shed is not a pharmacy and does not dispense medications. Prescriptions are fulfilled and shipped by a licensed third-party dispensing pharmacy.

‍